NCT03227029View on ClinicalTrials.gov

Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

September 22, 2017

Primary Completion Date

December 19, 2019

Study Completion Date

October 1, 2020

Conditions
Respiratory Syncytial Virus Infections
Interventions
BIOLOGICAL

RSV ΔNS2/Δ1313/I1314L

10\^6 plaque-forming units (PFU); administered as nose drops

BIOLOGICAL

RSV 276

10\^5 PFU; administered as nose drops

BIOLOGICAL

Placebo

Isotonic diluent, administered as nose drops

Trial Locations (12)

10461

Jacobi Med. Ctr. Bronx NICHD CRS, The Bronx

11794

SUNY Stony Brook NICHD CRS, Stony Brook

21205

Johns Hopkins University Center for Immunization Research, Baltimore

60612

Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago

80045

Univ. of Colorado Denver NICHD CRS, Aurora

90089

Usc La Nichd Crs, Los Angeles

92093-0672

University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla

90095-1752

David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles

60614-3393

Lurie Children's Hospital of Chicago (LCH) CRS, Chicago

02118

Boston Medical Center Ped. HIV Program NICHD CRS, Boston

38105-3678

St. Jude Children's Research Hospital CRS, Memphis

77030-2399

Texas Children's Hospital CRS, Houston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03227029 - Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age | Biotech Hunter | Biotech Hunter